The Department of Pharmaceuticals (DoP) has rejected a review application of Sanofi India, part of the leading multinational pharma major Sanofi, and upheld the decision of National Pharmaceutical ...
Silver Spring, MD - The US Food and Drug Administration (FDA) has granted approval of the first generic formulation of enoxaparin (Lovenox, Sanofi-Aventis) sodium injection, a low-molecular-weight ...
(RTTNews) - Sandoz, Inc., an unit of Novartis Pharma AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high ...
The prophylaxis of thromboembolic disorders (deep vein thrombosis) in patients undergoing: orthopedic surgery of the hip or knee; high-risk abdominal, gynecological, or urological surgeries; ...
July 29, 2010 (Washington, DC) — Sanofi-Aventis, which makes enoxaparin sodium injection (Lovenox), has filed a lawsuit in federal court against the US Food and Drug Administration (FDA), seeking a ...
It is indicated alone or in combination with warfarin to prevent and treat blood clots in the leg. It is a low molecular weight heparin. Enoxaparin is indicated for preventing and treating blood clots ...
The U.S. Food and Drug Administration today approved the first generic version of Lovenox (enoxaparin sodium injection), an anti-coagulant drug used to prevent deep vein thrombosis (DVT), a ...
“We are very excited to bring our enoxaparin biosimilars Inclunox ® and Inclunox ® HP to market by building on our worldwide experience with biosimilars. The enoxaparin biosimilar market represents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback